

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/6550010>

9,19-Cyclolanostane Derivatives from the Roots of *Actaea pachypoda*

ARTICLE in JOURNAL OF NATURAL PRODUCTS · FEBRUARY 2007

Impact Factor: 3.8 · DOI: 10.1021/np060152t · Source: PubMed

CITATIONS

13

READS

42

5 AUTHORS, INCLUDING:



Zulfiqar Ali

University of Mississippi

265 PUBLICATIONS 1,371 CITATIONS

SEE PROFILE



Rahul S Pawar

U.S. Food and Drug Administration

49 PUBLICATIONS 546 CITATIONS

SEE PROFILE



Daneel Ferreira

University of Mississippi

402 PUBLICATIONS 7,806 CITATIONS

SEE PROFILE

9,19-Cyclolanostane Derivatives from the Roots of *Actaea pachypoda*

Zulfiqar Ali,[†] Shabana I. Khan,[†] Rahul S. Pawar,[†] Daneel Ferreira,^{†,‡} and Ikhlas A. Khan^{*,†,‡}

National Center for Natural Products Research and Department of Pharmacognosy, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, Mississippi 38677

Received April 5, 2006





Phytochemical investigation of the chemical constituents of the roots of *Actaea pachypoda* afforded 12 9,19-cyclolanostane type triterpenoids, including the new 7,8-dihydroactaeaepoxide 3-*O*- β -D-xylopyranoside (**1**), 12-deacetoxyactaeaepoxide 3-*O*- β -D-xylopyranoside (**2**), and 12 β -acetoxycimigenol (**3**). Their structures were determined by spectroscopic and chemical methods.

The genus *Actaea* (Ranunculaceae) was first described by Von Linné in 1735.¹ Owing to a lack of understanding of the delimitation of the genus and closely related genera, e.g., *Cimicifuga* and *Souliea*, and the species within the genus itself, the taxonomic debate is continuing. Some *Actaea* species were previously classified under the genus *Cimicifuga*, creating more taxonomical discord among closely related genera. Morphological and molecular analyses have also revealed supraspecific groupings within the genus.¹ Updated and concise taxonomic classification of *Actaea* versus *Cimicifuga* and *Souliea* was done via utilization of morphological and molecular data.¹ Accordingly, *Actaea* consists of 28 species distributed throughout East Asia, Europe, and North America.

Actaea racemosa L. [syn. *Cimicifuga racemosa* L. (Nutt.)], commonly known as black cohosh, is a well-known dietary supplement for women's health in alleviating menstrual pain and menopausal disorders. The roots of *A. pachypoda* are used to ease pain during childbirth.² Black cohosh has been investigated extensively and found to contain cycloartane type triterpenes^{3–7} and phenylpropanoid derivatives.^{8,9} It is usually collected from the wild in North America, where it often coexists with the closely related *A. pachypoda* (white cohosh).¹⁰

In order to differentiate *A. pachypoda* and black cohosh, we undertook a phytochemical investigation of the largely unexplored constituents of white cohosh. This paper describes the identification of three new 9,19-cyclolanostane triterpene derivatives, 7,8-dihydroactaeaepoxide 3-*O*- β -D-xylopyranoside (**1**), 12-deacetoxyactaeaepoxide 3-*O*- β -D-xylopyranoside (**2**), and 12 β -acetoxycimigenol (**3**), and nine known compounds from the MeOH extract of the roots of *A. pachypoda*. The structures of **1–3** were determined on the basis of spectroscopic and chemical methods.

Compound **1** showed a pseudomolecular ion in the positive ESIMS at m/z 701 $[M + Na]^+$. When considered in conjunction with its ¹³C NMR data, it indicated a molecular formula of C₃₅H₅₄O₉. The assignment of ¹H and ¹³C NMR spectroscopic data of **1** (Table 1) was based on HMQC, HMBC (Figure 1), and ¹H–¹H COSY spectra. The ¹³C NMR spectrum showed 37 resonances, of which 30 were attributed to a triterpene skeleton, five to a pentose unit, and two to an acetyl group. A DEPT NMR experiment permitted differentiation of the 37 ¹³C NMR resonances into eight methyl, eight methylene, 13 methine, and eight quaternary carbons. Characteristic resonances in the ¹H and ¹³C NMR spectra (Table 1) for an isolated cyclopropane methylene [$\delta_{H/C}$ 0.20, 0.54/30.0 (C-19)], six tertiary methyls [$\delta_{H/C}$ 0.85/ 20.0 (C-28), 0.99/ 15.6 (C-30), 1.30/ 26.0 (C-29), 1.34/ 14.0 (C-18), 1.67/ 25.1 (C-26), and 1.73/ 28.1 (C-27)], and a secondary methyl [$\delta_{H/C}$ 1.30/ 17.7



(C-21)] indicated a 9,19-cyclolanostane type triterpene architecture.^{3–7} Several resonances due to oxygenated carbons in the ¹³C NMR spectrum of **1** at δ_C 88.4 (C-3), 77.3 (C-12), 72.4 (C-16), 87.0 (C-22), 105.9 (C-23), 83.6 (C-24), 83.9 (C-25), and 170.8 (C-OCOMe) and the resonances of a pentosyl moiety at δ_C 107.7 (C-1'), 75.8 (C-2'), 78.8 (C-3'), 71.5 (C-4'), and 67.3 (C-6') indicated a significant degree of *O*-decoration. The correlations of H-12 (δ_H 5.12) and a methyl resonance at δ_H 2.07 with a carbonyl carbon at δ_C 170.8 in the HMBC spectrum (Figure 1) indicated an *O*-acetyl group at C-12. Similarly, the correlations of an anomeric proton at

* To whom correspondence should be addressed. Tel: 1-662-915-7821. Fax: 1-662-915-7989. E-mail: ikhan@olemiss.edu.

[†] National Center for Natural Products Research.

[‡] Department of Pharmacognosy.

Table 1. ^1H and ^{13}C NMR Data for Compounds **1–4**

position	1		2		3		4	
	δ_{C} , mult.	δ_{H} mult. (J in Hz)	δ_{C} , mult.	δ_{H} mult. (J in Hz)	δ_{C} , mult.	δ_{H} mult. (J in Hz)	δ_{C} , mult.	δ_{H} mult. (J in Hz)
1	32.3 t	1.07	30.7 t	1.17	32.9 t	1.07	32.7 t	1.10
		1.47		1.57		1.47		1.56
2	30.2 t	1.27	29.9 t	1.92	31.5 t	1.83	30.4 t	1.89
		2.23		2.24		1.94		2.28
3	88.4 d	3.34 brd (10.4)	88.5 d	3.48 dd (11.2, 4.0)	78.1 d	3.51 dd (11.6, 4.4)	88.6 d	3.48 dd (11.6, 4.0)
4	41.5 s		40.7 s		41.3 s		41.6 s	
5	47.3 d	1.25	43.0 d	1.28	47.4 d	1.25 dd (13.0, 4.8)	47.5 d	1.27
6	20.8 t	0.72	22.2 t	1.56	21.3 t	0.80	21.0 t	0.74
		1.43		1.87		1.55		1.49
7	26.1 t	0.97	113.6 d	5.12 brd (6.0)	26.5 t	1.22	26.3 t	1.10
		1.25				2.16		2.07
8	45.9 d	1.54	150.0 s		47.8 d	1.78 dd (12.8, 5.2)	47.5 d	1.76 dd (12.8, 4.8)
9	20.3 s		21.4 s		20.4 s		20.5 s	
10	27.0 s		28.6 s		27.4 s		27.1 s	
11	37.1 t	1.13	25.6 t	1.11	38.0 t	1.16	37.8 t	1.18
		2.71 dd (9.2, 16.0)		2.07		2.97 dd (16.0, 9.6)		2.94 dd (16.0, 9.2)
12	77.3 d	5.12 d (8.4)	33.5 d	1.32	77.7 d	5.29 dd (9.3, 2.4)	77.6 d	5.27 brd (7.2)
				1.71				
13	49.7 s		45.0 s		46.6 s		46.6 s	
14	48.5 s		50.7 s		48.8 s		48.8 s	
15	43.3 t	1.70	42.3 t	1.93	79.5 d	4.41 s	79.5 d	4.38 s
		1.91		2.12 dd (12.0, 7.6)				
16	72.4 d	5.01	72.9 d	5.07 q (7.6)	112.3 s		112.3 s	
17	52.8 d	1.81	53.2 d	1.61	59.6 d	1.70 brs	59.5 d	1.68 brs
18	14.0 q	1.34 s	23.3 q	1.21 s	13.0 q	1.36 s	13.0 q	1.33 s
19	30.0 t	0.20 brs	28.7 t	0.97 d (3.6)	31.4 t	0.34 d (4.4)	31.2 t	0.30 d (3.2)
		0.54 brs		0.45 d (3.6)		0.64 d (4.4)		0.60 d (3.2)
20	34.7 d	2.21	35.0 d	2.23	24.4 d	1.66	24.4 d	1.66
21	17.7 q	1.30 brs	17.8 q	1.25 d (6.0)	20.3 q	0.96 d (6.0)	20.3 q	0.95 brs
22	87.0 d	3.85 d (10.4)	87.1 d	3.91 d (10.8)	38.9 t	1.08	38.9 t	1.03
						2.32		2.31
23	105.9 s		106.4 s		71.8 d	4.76 d (8.8)	71.8 d	4.74 d (9.2)
24	83.6 d	4.19 s	83.6 d	4.19 s	90.3 d	3.78 s	90.2 d	3.77 s
25	83.9 s		83.9 s		71.3 s		71.3 s	
^a 26	25.1 q	1.67 s	25.2 q	1.67 s	25.8 q	1.48 s	25.8 q	1.47 s
^a 27	28.1 q	1.73 s	28.2 q	1.78 s	27.4 q	1.50 s	27.3 q	1.49 s
28	20.0 q	0.85 s	27.1 q	1.08 s	12.3 q	1.23 s	12.2 q	1.21 s
29	26.0 q	1.30 s	26.1 q	1.35 s	26.4 q	1.85 s	26.0 q	1.29 s
30	15.6 q	0.99 s	14.6 q	1.05 s	15.2 q	1.06 s	15.7 q	1.02 s
OAce	170.8 s	2.07 s			170.9 s	2.14 s	170.8 s	2.12 s
	21.9 q				22.0 q		22.0 q	
1'	107.7 d	4.82 d (7.9)	107.8 d	4.85 d (8.0)			107.8 d	4.83 d (8.0)
2'	75.8 d	3.99 t (7.9)	75.9 d	4.03 t (8.0)			75.9 d	4.01 t (8.0)
3'	78.8 d	4.13 t (7.9)	78.9 d	4.15 t (8.0)			78.9 d	4.14 t (8.0)
4'	71.5 d	4.17 (overlapped)	71.6 d	4.22 (overlapped)			71.5 d	4.19 dd (9.6, 4.8)
5'	67.3 t	3.70 t (10.8)	67.4 t	3.73 t (10.8)			67.4 t	3.71 t (10.8)
		4.33 dd (10.8, 4.8)		4.36 dd (10.8, 4.8)				4.33 dd (10.8, 4.8)

^a May be interchanged.

δ_{H} 4.82 ($^3J = 7.9$ Hz) with C-3 (δ_{C} 88.4) and that of H-3 (δ_{H} 3.34) with C-1' (δ_{C} 107.7) located the sugar moiety at C-3. The NMR spectroscopic data of compound **1** showed close resemblance with those of actaeapoxide 3-*O*- β -D-xylopyranoside⁶ except for significant changes at or around the C-7–C-8 bond. This reflected the presence of a C-7–C-8 single bond in **1** instead of the olefinic bond in actaeapoxide 3-*O*- β -D-xylopyranoside.⁶ The sugar obtained after acid hydrolysis was identified as D-xylose by comparing its TLC and specific rotation with a D-xylose authentic sample. The relative configuration of **1** was assigned on the basis of coupling constants, molecular models, and a NOESY experiment (Figure 2). The NOESY associations of H-3 with H-5; H-12 with H-17 and Me-28; H-17 with H-12, H-16, Me-21, H-22, and Me-28; and Me-21 with H-17 and H-22 suggested a β -orientation of the substituents at C-3, C-12, C-16, and C-22 (Figure 2), similar to actaeapoxide 3-*O*- β -D-xylopyranoside.⁶ Under the constraints of the β -oriented *O*-substitution at C-16 and C-22, a Dreiding model was consistent only with an α -oriented C-23–C-24 oxirane functionality. Compound **1** is thus 7,8-dihydroactaeapoxide 3-*O*- β -D-xylopyranoside.

Compound **2** showed a molecular $[\text{M} + \text{Na}]^+$ ion at m/z 641.3670 in the positive HRESIMS, indicative of a molecular formula of

$\text{C}_{35}\text{H}_{54}\text{O}_9$. When its ^1H and ^{13}C NMR data (Table 1) were compared with those of actaeapoxide 3-*O*- β -D-xylopyranoside,⁶ the resonances of an *O*-acetyl group were absent in **2**, showing instead a methylene functionality at C-12. The assignments of the ^1H and ^{13}C NMR data were facilitated by comparison with those of actaeapoxide 3-*O*- β -D-xylopyranoside⁶ and confirmed by HMQC, HMBC (Figure 1), and ^1H – ^1H COSY data. The relative configuration of **2** was determined in a similar manner to that of 7,8-dihydroactaeapoxide 3-*O*- β -D-xylopyranoside (**1**). Accordingly, compound **2** was characterized as 12-deacetoxyactaeapoxide 3-*O*- β -D-xylopyranoside.

The positive ESIMS of compound **3** showed an $[\text{M} + \text{Na}]^+$ molecular ion at m/z 569, which, in conjunction with ^{13}C NMR data, established the molecular formula $\text{C}_{32}\text{H}_{50}\text{O}_7$. The 32 resonances in the ^{13}C NMR spectrum of **3** indicated a triterpenoid backbone bearing an *O*-acetyl group. Assignment of ^1H and ^{13}C NMR data (Table 1) in the usual manner (Figures 1 and 2) indicated that compound **3** comprised the unreported aglycon of 12- β -acetoxycimigenol 3-*O*- β -D-xylopyranoside (**4**)¹¹ and cimracemoside D.⁵ Significant NOESY correlations (Figure 2) of H-12 with H-17 and Me-28; H-17 with H-12, Me-21, H-24, and Me-28; and H-3 with H-5 indicated their α -orientation, whereas the associations of




Figure 1. HMBC correlations of (a) compounds **1** and **2**, (b) compound **1**, (c) compound **2**, and (d) compounds **3** and **4**.




Figure 2. NOESY correlations of compounds **1** and **3**.

H-19 with H-8 and Me-30; H-8 with H-15, Me-18, and H-19; and H-15 with H-8 and Me-18, revealed their β -orientation. Thus, compound **3** is 12 β -acetoxycimigenol.

12 β -Acetoxycimigenol 3-*O*- β -D-xylopyranoside (**4**)¹¹ and similar compounds^{5,7} were reported earlier. According to these reports, the ¹³C NMR chemical shifts of C-13 and C-14 were assigned at δ_C 48.4 (48.5) and 46.1 (46.3), respectively. We have assigned the chemical shifts of C-13 and C-14 in both **3** and **4** at δ_C 46.6 and 48.8, respectively, on the basis of the HMBC correlation of H-11 (δ_H 2.94) to C-13 (δ_C 46.6) (Figures 1 and S1, Supporting Information).

Known compounds were characterized as 12 β -acetoxycimigenol 3-*O*- β -D-xylopyranoside (**4**)¹¹, actaeapoxide 3-*O*- β -D-xylopyranoside (**5**)⁶, cimigenol 3-*O*- β -D-xylopyranoside (**6**)⁶, 23-acetylshengmanol 3-*O*- β -D-xylopyranoside (**7**)⁴, 23-*epi*-26-deoxyactein (**8**)³, 25-*O*-acetylcimigenol 3-*O*- β -D-xylopyranoside,¹² 25-*O*-methylcimigenol 3-*O*- β -D-xylopyranoside,¹² cimigenol,¹³ and 24-*O*-acetylhydroshengmanol 3-*O*- β -D-xylopyranoside.¹⁴

Compounds **1**–**8** did not show cytotoxic, estrogenic, antioxidant, and anticomplement activity, except 12 β -acetoxycimigenol (**3**), which exhibited moderate anticomplement activity (see Supporting Information).

Experimental Section

General Experimental Procedures. Optical rotations were measured on a Rudolph Research Auto Pol IV polarimeter. IR spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer. NMR spectra were recorded on a Varian AS 400 NMR spectrometer in pyridine-*d*₅. ESIMS data were obtained on an Agilent Series 1100 SL mass spectrometer. Gravity column chromatography was performed using silica gel (J.T.Baker, 40 μ m for flash chromatography) and reversed-phase RP-18 silica (Polarbond, J.T.Baker). TLC was carried out on silica gel 60 F₂₅₄ plates (Merck, Germany).

Plant Material. The roots of *A. pachypoda* Elliott were collected in Madison County, NC (August 2004), and identified by Mr. G. Gust, William L. Brown Center, Missouri Botanical Garden, St. Louis, MO. A voucher specimen (FDA #4) has been deposited at the Missouri Botanical Garden.

Extraction and Isolation. The freeze-dried roots of *A. pachypoda* were ground, and the resultant powder (382 g) was extracted with MeOH (0.75 L \times 24 h \times 5). The combined extract was evaporated under reduced pressure to afford a brown powder (28 g). A portion of this powder (22.0 g) was subjected to column chromatography on flash silica gel (40 μ m) and eluted with mixtures of EtOAc–CHCl₃–MeOH–H₂O (15:8:4:1) to obtain fractions F1 (1.1 g) and F2 (6.7 g). Elution with a 12:8:8:2 mixture afforded fractions F3 (0.78 g) and F4 (4.1 g), followed by fraction F5 (2.2 g) on elution with MeOH. Fraction F2 (6.0 g) was resolved into 13 subfractions (F2A–F2M) by column chromatography over reversed-phase silica gel (RP-18, MeOH–H₂O, 7:3). Actaeapoxide 3-*O*- β -D-xylopyranoside (**5**, 41 mg) was purified from fraction F2D (130 mg) by column chromatography (silica gel, EtOAc–CHCl₃–MeOH–H₂O, 15:8:4:1). Fraction F2E (1.0 g) was subjected to further column chromatography, initially over silica gel (EtOAc–CHCl₃–MeOH, 12:6:1) and then over octadecylsilyl silica gel (MeOH–H₂O, 7:3) to yield 7,8-dihydroactaeapoxide 3-*O*- β -D-xylopyranoside (**1**, 117 mg) and actaeapoxide 3-*O*- β -D-xylopyranoside (**5**, 169 mg). 23-*epi*-26-Deoxyactein (**8**, 52 mg) was obtained from fraction F2F (173 mg) via column chromatography (silica gel, CHCl₃–MeOH, 16:1). 23-Acetylshengmanol 3-*O*- β -D-xylopyranoside (**7**, 128 mg) and 12 β -acetoxycimigenol 3-*O*- β -D-xylopyranoside (**4**, 170 mg) were purified from fraction F2H (1.1 g) by column chromatography over silica gel (CHCl₃–MeOH–H₂O, 9:1:0.7, and EtOAc–CHCl₃–MeOH, 12:6:1). Purification of fraction F2J (365 mg) on silica gel (EtOAc–CHCl₃–MeOH, 12:6:1) afforded 12 β -acetoxycimigenol (**3**, 14 mg), 24-*O*-acetylhydroshengmanol 3-*O*- β -D-xylopyranoside (87.9 mg), and impure deacetoxyactaeapoxide 3-*O*- β -D-xylopyranoside. 12-Deacetoxyactaeapoxide 3-*O*- β -D-xylopyranoside (**2**) was purified (41 mg) by column chromatography over reversed-phase silica gel (MeOH–H₂O, 8:2). Cimigenol 3-*O*- β -D-xylopyranoside (**6**, 72 mg), 25-*O*-acetylcimigenol 3-*O*- β -D-xylopyranoside, 25-*O*-methylcimigenol 3-*O*- β -D-xylopyranoside (75 mg), and cimigenol (12 mg) were obtained from fraction F2M (871 mg) by column chromatography over silica gel (EtOAc–CHCl₃–MeOH, 12:6:1).

7,8-Dihydroactaeapoxide 3-*O*- β -D-xylopyranoside (1**):** white powder; $[\alpha]_D^{25}$ –55.3 (c 0.13, MeOH); IR (KBr) ν_{\max} 3415, 2949, 1728, 1638 cm^{–1}; ¹H and ¹³C NMR, Table 1; positive ESIMS m/z 701 [M + Na]⁺; HRESIMS m/z 701.3883 (calcd for C₃₇H₅₈NaO₁₁, 701.3877).

12-Deacetoxyactaeapoxide 3-*O*- β -D-xylopyranoside (2**):** white powder; $[\alpha]_D^{25}$ –26.5 (c 0.40, MeOH); IR (KBr) ν_{\max} 3416, 2926, 1645 cm^{–1}; ¹H and ¹³C NMR, Table 1; positive ESIMS m/z 641 [M + Na]⁺; HRESIMS m/z 641.3670 (calcd for C₃₅H₅₄NaO₉, 641.3666).

12 β -Acetoxycimigenol (3**):** white powder; $[\alpha]_D^{25}$ –16.7 (c 1.2, MeOH); IR (KBr) ν_{\max} 3428, 2929, 1731, 1652 cm^{–1}; ¹H and ¹³C NMR, Table 1; positive ESIMS m/z 569 [M + Na]⁺; HRESIMS m/z 569.3445 (calcd for C₃₂H₅₀NaO₇, 569.3454).

Acid Hydrolysis and Identification of the Sugar Moieties in Compounds **1 and **2**.** Compounds **1** and **2** (15 mg) were separately refluxed with 0.5 N HCl (3 mL) for 2 h. Each reaction mixture was diluted with water and extracted with CHCl₃. The water layer was evaporated to dryness under reduced pressure to give a monosaccharide, which had an R_f (EtOAc–CHCl₃–MeOH–H₂O, 12:8:8:4) and specific rotation $[\alpha]_D^{25}$ +20.7 (c 0.5, H₂O) comparable to those of D-xylose (Sigma-Aldrich).

Acknowledgment. This work was supported by the United States Food and Drug Administration (FDA) (FD-U-002071-01) and the United States Department of Agriculture (USDA) (58-6408-2-0009).

We thank Mr. J. S. Miller, Mr. W. Applequist, Mr. G. Gust, Mr. J. Stone, and Mr. L. Nye, Missouri Botanical Garden, for providing the plant material, Dr. B. Avula for the MS data, and Ms. S. Porchia-White and Ms. S. Muktan for the biological assays.

Supporting Information Available: Biological testing results, protocols, and figure showing the HMBC NMR spectrum of compound **4**. This information is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) Compton, J. A.; Culham, A.; Jury, S. L. *Taxon* **1998**, *47*, 593–634.
- (2) Foster, S.; Duke, J. A. *A Field Guide to Medicinal Plants: Eastern and Central North America*; Houghton Mifflin Co: Boston, 1990.
- (3) Kusano, A.; Shibano, M.; Tsukamoto, D.; Kusano, G. *Chem. Pharm. Bull.* **2001**, *49*, 437–441.
- (4) Watanabe, K.; Mimaki, Y.; Sakagami, H.; Sashida, Y. *Chem. Pharm. Bull.* **2002**, *50*, 121–125.
- (5) Shao, Y.; Harris, A.; Wang, M.; Zhang, H.; Cordell, G. A.; Bowman, M.; Lemmo, E. *J. Nat. Prod.* **2000**, *63*, 905–910.
- (6) Wende, K.; Mugge, C.; Thurow, K.; Schopke, T.; Lindequist, U. *J. Nat. Prod.* **2001**, *64*, 986–989.
- (7) Chen, S.; Fabricant, D. S.; Santarsiero, B. D.; Mesecar, A. D.; Fitzloff, J. F.; Fong, H. H. S.; Farnsworth, N. R. *J. Nat. Prod.* **2002**, *65*, 601–605.
- (8) Nuntanakorn, P.; Jiang, B.; Einbond, L. S.; Yang, H.; Kronenberg, F.; Weinstein, I. B.; Kennelly, E. J. *J. Nat. Prod.* **2006**, *69*, 314–318.
- (9) Chen, S.; Fabricant, D. S.; Lu, Z.; Zhang, H.; Fong, H. H. S.; Farnsworth, N. R. *Phytochemistry* **2002**, *61*, 409–413.
- (10) Zerega, N. J. C.; Mori, S.; Lindqvist, C.; Zheng, Q.; Motley, T. J. *Econ. Bot.* **2002**, *56*, 154–164.
- (11) Lai, G. F.; Wang, Y.-F.; Fan, L.-M.; Cao, J.-X.; Luo, S.-D. *J. Asian Nat. Prod. Res.* **2005**, *7*, 695–699.
- (12) Takemoto, T.; Kusano, G.; Kawahara, H. *Yakugaku Zasshi* **1970**, *90*, 64–68.
- (13) Kusano, G.; Idoji, M.; Sogoh, Y.; Shibano, M.; Kusano, A.; Iwashita, T. *Chem. Pharm. Bull.* **1994**, *42*, 1100–1110.
- (14) Kimuro, O.; Sakurai, N.; Inoue, T. *Yakugaku Zasshi* **1983**, *103*, 293–299.

NP060152T